Petosemtamab is a dual-target monoclonal antibody that selectively binds to both epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5). Expressed in Chinese hamster ovary (CHO) cells genetically engineered to lack the fucosyltransferase 8 gene (FUT8), this modification results in a fucose-deficient antibody that exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC). With dissociation constants (Kd) of 0.22 nM for EGFR and 0.86 nM for LGR5, Petosemtamab effectively inhibits EGFR signaling and induces receptor degradation in LGR5-positive cancer cells. This antibody is particularly relevant for research into solid tumors, including head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC), providing a valuable tool for studies aimed at understanding and potentially intervening in the pathways involved in these malignancies.
Petosemtamab is a dual-target monoclonal antibody that selectively binds to both epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5). Expressed in Chinese hamster ovary (CHO) cells genetically engineered to lack the fucosyltransferase 8 gene (FUT8), this modification results in a fucose-deficient antibody that exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC). With dissociation constants (Kd) of 0.22 nM for EGFR and 0.86 nM for LGR5, Petosemtamab effectively inhibits EGFR signaling and induces receptor degradation in LGR5-positive cancer cells. This antibody is particularly relevant for research into solid tumors, including head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC), providing a valuable tool for studies aimed at understanding and potentially intervening in the pathways involved in these malignancies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
